Table 3.
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
Variable* | No. of cases | Median OS (95%CI)* | p† | HR (95%CI) | p$ | |
Gender | Male | 82 | 10.5 (9.4–11.6) | 0.789 | ||
Female | 53 | 11.6 (9.9–13.3) | ||||
Age (year) | ≥ 65 | 56 | 10.6 (9.1–12.1) | 0.973 | ||
< 65 | 79 | 11.4 (9.9–12.9) | ||||
EGCO PS + | ≥ 2 | 48 | 9.9 (7.7–12.1) | 0.159 | ||
< 2 | 87 | 11.8 (10.1–13.5) | ||||
Bismuth type ‡ | III–IV | 31 | 7.6 (6.0–9.2) | 0.000 | 2.778 (1.765, 4.371) | 0.000 |
I–II | 104 | 12.1 (10.3–13.9) | ||||
Distant metastasis | Yes | 58 | 10.3 (9.2–11.4) | 0.021 | 1.708 (1.171, 2.491) | 0.005 |
No | 77 | 11.8 (10.5–13.1) | ||||
CA 125 (U/mL) | > 40 | 71 | 10.6 (9.0–12.2) | 0.976 | ||
≤ 40 | 64 | 11.4 (10.1–12.7) | ||||
CA 19-9 (U/mL) | > 40 | 118 | 10.9 (9.9–11.9) | 0.190 | ||
≤ 40 | 17 | 9.1 (4.4–13.8) | ||||
Length of stricture (cm) | ≥ 4 | 60 | 9.1 (8.0–10.3) | 0.000 | 1.727 (1.124, 2.654) | 0.013 |
< 4 | 75 | 13.4 (11.1–15.7) | ||||
Length of stent (mm) | > 6 | 48 | 10.2 (8.2–12.2) | 0.379 | ||
≤ 6 | 87 | 11.6 (9.9–13.3) | ||||
Stent placement | Following | 57 | 10.9 (9.5–12.3) | 0.365 | ||
Synchronising | 78 | 10.7 (9.2–12.2) |
*OS data are in months, and the Kaplan–Meier method was used
†The long-rank test was used
$Cox regression was used
+According to the Toxicity and response criteria of the Eastern Cooperative Oncology Group
‡According to the Bismuth classification of perihilar cholangiocarcinoma
OS, overall survival; CA125/19-9, carbohydrate antigen 125/19-9